Peer Exchange

Expert panelists share insight on the current treatment landscape of cervical cancer, locally advanced and metastatic, in light of recent clinical studies and drug approvals.

Updates in the prevention and management of chemotherapy-induced neutropenia, specifically in breast cancer, with special considerations for the impact of new data on practice patterns.

A discussion on how to apply updated data from ESMO 2021 to treatment decisions for patients with HR+/HER2- advanced breast cancer.

Reactions to treatment advances and new FDA approvals in prostate cancer, and insight regarding the valuable role that precision medicine plays in genitourinary oncology.

Mark Socinski, MD, Gilberto Lopes, MD, Afsaneh Barzi, MD, PhD, and Jack West, MD, discuss the balance of using innovative cancer therapies with disruptive drug prices to make the therapies more widely available.

An overview of data supporting exciting developments in hepatocellular carcinoma using systemic therapy in various treatment settings.

Key opinion leaders review clinical cases in systemic mastocytosis, focusing on therapeutic options and diagnostic criteria.

A panel of experts in thoracic oncology discuss the potential impact of recent clinical data on treatment of small cell lung cancer.

A discussion about several topics pertaining to the treatment of CLL including the latest research in the field and the impact of recent clinical trial data on making treatment decisions for your patients.

Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, discuss modern approaches to the management of multiple myeloma and review recent data presented at the 2021 ASCO Annual Meeting.

The latest research and impact of recent clinical trials on treatment selection using erythropoiesis stimulating and hypomethylating agents for myelodysplastic syndrome.

A discussion regarding the potential implications of treating renal cell carcinoma based on recent clinical trial data and key presentations from the 2021 ASCO virtual meeting.

Systemic treatment options available for HER2+ metastatic breast cancer based on recent clinical trial data and abstract presentations from the ASCO 2021 virtual meeting.

Experts discuss advancements in the development of targeted agents in oncogene-driven non–small cell lung cancer, highlight the results from key clinical trials presented at the American Society of Clinical Oncology 2021 Annual Meeting, and provide insights on how these findings may support treatment decision making in an era of precision medicine.

Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, discuss systemic therapy and recent clinical trial data presented at the 2021 ASCO Annual Meeting for hormone receptor-positive breast cancer.

The latest research and impact of recent clinical trials on treatment selection using immunotherapy-based regimens for metastatic non–small cell lung cancer (NSCLC), consolidation immunotherapy in stage III disease, and perioperative regimens with immunotherapy in resectable NSCLC.

A panel of experts in the management of myeloproliferative neoplasms provides a lively discussion on current and emerging treatment options for patients with primary myelofibrosis or polycythemia vera.

Graft-vs-Host Disease (GVHD) is a challenging complication of allogeneic transplantation. In this peer exchange, leaders in the field will share their thoughts on the biology and presentation of GVHD, the diagnosis and staging of GVHD, initial management of GVHD, and steroid-refractory GVHD.